SELB Selecta Biosciences Inc.

1.71
+0.05  (+3%)
Previous Close 1.66
Open 1.66
Price To Book 5.18
Market Cap 76,587,523
Shares 44,788,025
Volume 122,283
Short Ratio
Av. Daily Volume 291,425

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due 4Q 2019 and full data 1Q 2020. Phase 3 trial to be initiated 4Q 2019.
SEL-212 (COMPARE) - Head to head trial vs Krystexxa
Tophaceous gout
Grade 5 SAE reported October 17, 2018.
SEL-403
Mesothelioma

Latest News

  1. Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical Officer
  2. Polaris Venture Management Co. V, L.L.C. Buys Selecta Biosciences Inc
  3. Does Selecta Biosciences, Inc. (NASDAQ:SELB) Have A Particularly Volatile Share Price?
  4. How Does Selecta Biosciences, Inc. (NASDAQ:SELB) Affect Your Portfolio Volatility?
  5. Could Selecta Biosciences, Inc.'s (NASDAQ:SELB) Investor Composition Influence The Stock Price?
  6. Selecta Biosciences Sees Hammer Chart Pattern: Time to Buy?
  7. The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
  8. Selecta Biosciences Announces Appointment of Scott D. Myers to Board of Directors
  9. The Selecta Biosciences (NASDAQ:SELB) Share Price Is Down 84% So Some Shareholders Are Rather Upset
  10. Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019
  11. Selecta Biosciences to Present at the Jefferies Healthcare Conference on June 06, 2019
  12. Edited Transcript of SELB earnings conference call or presentation 9-May-19 12:30pm GMT
  13. Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
  14. Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call
  15. Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
  16. Will Selecta Biosciences Continue to Surge Higher?
  17. Selecta Biosciences to Present at the Needham & Company 18th Annual Healthcare Conference April 9, 2019
  18. Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
  19. Selecta Biosciences Announces New Employment Inducement Grant
  20. Edited Transcript of SELB earnings conference call or presentation 15-Mar-19 12:30pm GMT